PA8558201A1 - Derivados de benzotiazol - Google Patents

Derivados de benzotiazol

Info

Publication number
PA8558201A1
PA8558201A1 PA20028558201A PA8558201A PA8558201A1 PA 8558201 A1 PA8558201 A1 PA 8558201A1 PA 20028558201 A PA20028558201 A PA 20028558201A PA 8558201 A PA8558201 A PA 8558201A PA 8558201 A1 PA8558201 A1 PA 8558201A1
Authority
PA
Panama
Prior art keywords
optionally replaced
ilo
phenyl
rent
benzo
Prior art date
Application number
PA20028558201A
Other languages
English (en)
Inventor
Alexander Flohr
Claus Riemer
Roland Jakob-Roetne
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8558201A1 publication Critical patent/PA8558201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL EN DONDE R ES HIDROGENO, - (CH2)N-FENILO, OPCIONALMENTE SUSTITUIDO POR HALOGENO, ALQUILO INFERIOR, ALCOXILO INFERIOR, TRIFLUOROMETILO O -N(R´)-C(O)-ALQUILO INFERIOR,-(CH2)N-PIRIDINILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR,-(CH2)N-C3-6-CICLOALQUILO, OPCIONALMENTE SUSTITUIDO POR HIDROXILO,-(CH2)N-N(R´) -C3-6-CICLOALQUILO,-(CH2)N-BENZO [1,3]-DIOXILO,-(CR´2)-TIOFENILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR,-(CR´2)N-TIAZOLILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR,-(CH2)N-C(O)-TIOFENILO, OPCIONALMENTE SUSTITUIDO POR HALOGENO,-(CH2)N-FURANILO, OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR,-(CH2)N-C(O)-(CH2)N-TIOFENILO,-(CHR´)N-BENZOFURAN-2-ILO,-(CH2)N-BENZO[B]TIOFENILO,OPCIONALMENTE SUSTITUIDO POR ALQUILO INFERIOR, -(CH2)N-N(R´)-C(O)-FENILO, OPCIONALMENTE SUSTITUIDO POR HALOGENO O ALCOXILO INFERIOR, -(CH2)N-C(O)-FENILO, OPCIONALMENTE SUSTITUIDO POR ALCOXILO INFERIOR, -(CH2)N-C(O)-2, 3-DIHIDRO-BENZO[1,4]DIOXIN-6-ILO, -(CH2)N-N(R´)-C(O)-PIRIDINILO,-(CH2)N-TETRAHIDROFURANILO,-CH-BI-FENILO,-CH(FENIL)-PIRIDINILO, -(CH2)N-1-OXO-1-OXO-1, 3-DIHIDRO-ISOINDOL-2-ILO, -(CH2)N-1, 3-DIOXO-1,3-DIHIDRO-ISOINDOL -2-ILO, -(CH2)N-CH(FENIL)-TETRAHIDROPIRANILO, -(CH2)N-1-OXO-1,2,3,4-TETRAHIDRO-ISOQUINOLIN-3-IL O -(CH2)N-S-[1,3,4]TIAZOL-2-ILO, OPCIONALMENTE SUSTITUIDO POR AMINO; ES HIDROGENO O ALQUILO INFERIOR, INDEPENDIENTEMENTE UNO DEL OTRO EN EL CASO DE R´2; Y N ES 0,1,2,3 O 4; Y LAS SALES DE ADICION ACIDA FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. LOS COMPUESTOS DE FORMULA I TIENEN UNA BUENA AFINIDAD POR EL RECEPTOR A2A Y ESTOS SON POR LO TANTO UTILES EN EL TRATAMIENTO DE ENFERMEDADES, RELACIONADAS CON ESTE RECEPTOR.
PA20028558201A 2001-11-27 2002-11-22 Derivados de benzotiazol PA8558201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01127442 2001-11-27

Publications (1)

Publication Number Publication Date
PA8558201A1 true PA8558201A1 (es) 2003-09-05

Family

ID=8179277

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028558201A PA8558201A1 (es) 2001-11-27 2002-11-22 Derivados de benzotiazol

Country Status (21)

Country Link
US (1) US6596718B1 (es)
EP (1) EP1450796B1 (es)
JP (1) JP4216193B2 (es)
KR (1) KR100613197B1 (es)
CN (1) CN1325052C (es)
AR (1) AR037418A1 (es)
AT (1) ATE391505T1 (es)
AU (1) AU2002352045B2 (es)
BR (1) BR0214455A (es)
CA (1) CA2467825A1 (es)
DE (1) DE60226063T2 (es)
ES (1) ES2303558T3 (es)
GT (1) GT200200240A (es)
MX (1) MXPA04004982A (es)
PA (1) PA8558201A1 (es)
PE (1) PE20030735A1 (es)
PL (1) PL370978A1 (es)
RU (1) RU2293083C2 (es)
TW (1) TW200408391A (es)
UY (1) UY27551A1 (es)
WO (1) WO2003045385A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
US6678828B1 (en) * 2002-07-22 2004-01-13 Vormetric, Inc. Secure network file access control system
MXPA05012360A (es) 2003-05-19 2006-02-02 Hoffmann La Roche Derivados de benzotiazol como ligandos receptores de adenosina.
JP4795022B2 (ja) * 2003-09-30 2011-10-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗真菌剤
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
JPWO2005073210A1 (ja) * 2004-01-28 2007-09-06 キッセイ薬品工業株式会社 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
US8064040B2 (en) * 2004-03-30 2011-11-22 Carl Zeiss Smt Gmbh Projection objective, projection exposure apparatus and reflective reticle for microlithography
MX2007000635A (es) * 2004-07-22 2007-03-07 Hoffmann La Roche Benzotiazoles sustituidos.
JPWO2006016548A1 (ja) * 2004-08-09 2008-05-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗マラリア剤
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd A PYRIDINE DERIVATIVE ANTIPILIC AGENT
WO2006115134A1 (ja) * 2005-04-22 2006-11-02 Kissei Pharmaceutical Co., Ltd. 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
WO2008035726A1 (fr) * 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
CN101547923A (zh) 2006-12-07 2009-09-30 弗·哈夫曼-拉罗切有限公司 作为via受体拮抗剂的螺环-哌啶衍生物
WO2008077811A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
US20080153863A1 (en) 2006-12-22 2008-06-26 Caterina Bissantz Spiropiperidine derivatives
CN102702185A (zh) * 2007-04-27 2012-10-03 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐的结晶
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
PE20140868A1 (es) 2011-06-24 2014-07-18 Amgen Inc Antagonistas trpm8 y su uso en tratamientos
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018093696A1 (en) * 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
CN112638908A (zh) * 2018-09-04 2021-04-09 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的苯并噻唑类化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU96502A (sh) * 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Derivati benzotiazola

Also Published As

Publication number Publication date
KR100613197B1 (ko) 2006-08-21
JP4216193B2 (ja) 2009-01-28
ATE391505T1 (de) 2008-04-15
GT200200240A (es) 2003-07-30
TW200408391A (en) 2004-06-01
AU2002352045B2 (en) 2006-08-17
KR20040062968A (ko) 2004-07-09
DE60226063D1 (en) 2008-05-21
WO2003045385A1 (en) 2003-06-05
ES2303558T3 (es) 2008-08-16
CA2467825A1 (en) 2003-06-05
AR037418A1 (es) 2004-11-10
AU2002352045A1 (en) 2003-06-10
CN1731999A (zh) 2006-02-08
RU2004119438A (ru) 2006-01-10
DE60226063T2 (de) 2009-05-20
CN1325052C (zh) 2007-07-11
EP1450796B1 (en) 2008-04-09
RU2293083C2 (ru) 2007-02-10
US6596718B1 (en) 2003-07-22
PE20030735A1 (es) 2003-08-29
PL370978A1 (en) 2005-06-13
MXPA04004982A (es) 2004-08-11
UY27551A1 (es) 2003-06-30
BR0214455A (pt) 2004-11-03
EP1450796A1 (en) 2004-09-01
JP2005526007A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
PA8558201A1 (es) Derivados de benzotiazol
MA28010A1 (fr) Derives de piperazine et leur utilisation comme agents therapeutiques
DE60023318D1 (de) Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
ATE344033T1 (de) Vinylphenyl-derivate als glk-aktivatoren
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
CY1111876T1 (el) Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη
DK1317459T3 (da) Bicykliske pyrrolylamider som glucogenphosphorylase-inhibitorer
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
DE69818831D1 (de) Indolderivate als mcp-1 rezeptor antagonisten
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
FI942381A (fi) Aryylisubstituoituja heterosyklisiä yhdisteitä
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
DE69011318T2 (de) Diazinderivate als Angiotensin II Rezeptor Antagonisten.
FI970317A (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
ATE473967T1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
ATE240328T1 (de) Substituierte azaoxindolederivate
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
ATE418548T1 (de) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
DK1336407T3 (da) Præparat indeholdende en angiotensin-II-receptorantagonist og et diuretikum og anvendelse deraf til behandling af hypertension
NZ528997A (en) Sulfonamides